Trillium Reports 2015 Financial and Operating Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Oil settles lower on peace hopes, Saudi attacks limit losses
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
Leerink Partners Remains Bullish as Trillium Therapeutics (TRIL) Continues TTI-621 Development
March 10, 2016 7:48 AM ESTLeerink Partners maintained an Outperform rating on Trillium Therapeutics (NASDAQ: TRIL) price target of $20.00 (from $29.00). Earlier this year TRIL initiated dosing in its Ph I where TTI-621 will be evaluated as a monotherapy in patients with relapsed/refractory hematological malignancies. While TRIL has broadened its portfolio with the recent acquisition of... More



